Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T15:07:03.407Z.
Calculation as of: 2026-10-06T15:07:03.407Z.
Quote observation: 2026-10-06T15:05:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 521b0ab3da901f2a49dafbbedcb3688a082548b97bbb2cd5efdb729e6989e7c5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$118.99M
EV/Sales Ratio
4.42x
TTM Avg
33.01x
3Y Avg
61.00x
5Y Avg
61.00x
Market Cap
$124.04M
EV/Sales Ratio
29.05x
TTM Avg
110.46x
3Y Avg
110.46x
5Y Avg
110.46x
Market Cap
$117.37M
EV/Sales Ratio
61.22x
TTM Avg
54.20x
3Y Avg
33.22x
5Y Avg
26.89x
Market Cap
$117.03M
EV/Sales Ratio
11.71x
TTM Avg
18.19x
3Y Avg
13.45x
5Y Avg
23.44x
Market Cap
$115.69M
EV/Sales Ratio
13615.53x
TTM Avg
11863.26x
3Y Avg
8138.14x
5Y Avg
6150.74x
Market Cap
$115.09M
EV/Sales Ratio
19.58x
TTM Avg
23.83x
3Y Avg
20.50x
5Y Avg
102.56x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | $121.00M | N/A | N/A | N/A | N/A |
| enGene Holdings Inc. (ENGN)vs › | $121.92M | N/A | N/A | N/A | N/A |
| Cibus, Inc. (CBUS)vs › | $123.66M | 31.28x | 52.83x | 97.39x | 88.07x |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.99M | 4.42x | 33.01x | 61.00x | 61.00x |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $124.04M | 29.05x | 110.46x | 110.46x | 110.46x |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $117.37M | 61.22x | 54.20x | 33.22x | 26.89x |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.03M | 11.71x | 18.19x | 13.45x | 23.44x |
| Genelux Corporation (GNLX)vs › | $115.69M | 13615.53x | 11863.26x | 8138.14x | 6150.74x |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.09M | 19.58x | 23.83x | 20.50x | 102.56x |
| Coya Therapeutics, Inc. (COYA)vs › | $114.47M | N/A | 52.04x | 28.07x | 28.07x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
